Startup HDL Apomics Looks to Unlock Diagnostic Potential of High-Density Lipoproteins | GenomeWeb

NEW YORK (GenomeWeb) – High-density lipoproteins (HDLs) when combined with molecular diagnostics have the potential to enable greater success in tests for cardiovascular disease, and may have value in testing for a far broader range of diseases.

As a result, Allenhurst, New Jersey-based HDL Apomics is developing a technology platform that consists of a measurement matrix and analytics model to analyze relationships within the HDL proteome and generate results that could lead to better treatment for a number of diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.